Cannabics Pharmaceuticals is dedicated to the development of Personalized Anti-Cancer treatments.

Our main focus is the development of novel therapies and biotechnological tools aimed to providing relief from diverse ailments and treat human malignancies. These advanced tools include novel delivery systems, personalized medicine diagnostics and therapies based on Cannabinoid compounds.

Cannabics scientific research is devoted to create tailored therapies for cancer patients, utilizing advanced High-throughput screening (HTS) diagnostics and personalized bioinformatics tools.

The Company’s principal product is Cannabics SR' a long acting oil capsule that provides a safe, effective and reliable administration of cannabis. Composed solely from food grade materials, Cannabics SR' 5mg delivers a steady level of beneficial effects for 4–8 hours.

Cannabics Pharmaceuticals Inc. is traded in the US OTCQB stock exchange, under the trade symbol: CNBX

January 3, 2017 Cannabics Pharmaceuticals Announces a New Dosage of 5mg THC Cannabis Capsule Treating Cancer Patients. 

December 1, 2016 Cannabics Pharmaceuticals Announces Specific Ratios of Cannabinoids Led to Apoptosis in MDA-MB-231 Breast Cancer Cell Viability.

October 20, 2016 Cannabics Pharmaceuticals Discovers Specific Ratios of THC/CBD Effectuate Reduction in U87MG Glioblastoma Cell Viability

September 28, 2016 How this tiny Middle Eastern nation came to lead the world in medical marijuana research